Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medicaal Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from BeiGene Ltd. and Incyte Corporation.

Advances In™ Immunotherapy: Where Are We and Where Are We Going?

Release Date: June 29, 2021
Expiration Date: June 29, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data regarding immunotherapy in the treatment of cancer, with a forward-looking perspective on how new and novel agents might impact clinical practice. Clinical trial data, as well as the expanding role of immune checkpoint inhibitors in the treatment of solid tumors will be presented in a multimedia format and include a series of video interviews with an expert thought leader integrated into the text-based elements.

Acknowledgement of Commercial Support

This activity is supported by educational grants from BeiGene Ltd. and Incyte Corporation.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists who treat patients with cancer. Pathologists, nurses, nurse practitioners, physician assistants, and other health care professionals involved in the treatment and management of cancer will also be invited to participate in the activity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Examine immune escape mechanisms underlying the rationale for current and novel immunotherapies
  • Assess the efficacy and safety profiles of current and emerging immunotherapeutic agents
  • Evaluate the impact of emerging agents or combinations within the context of evolving treatment paradigms and resistance mechanisms

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Balazs Halmos, MD, MS
Balazs Halmos, MD, MS
Professor of Clinical Medicine
Director, Thoracic/Head and Neck Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx, NY

Disclosures: Grant/Research Support: AstraZeneca, BeiGene, GSK, Merck, BMS, Boehringer-lnqelheim, Amgen, Novartis, Pfizer, Advaxis, Blueprint, Elevation, AbbVie, Daiichi, Janssen. Consultant: Merck, TPT, Apollomics, BMS, BeiGene, Boehringer-lngelheim, Daiichi, Amgen, AstraZeneca, Pfizer, Novartis.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By